{"id":"W4391933719","doi":"10.1016/j.annonc.2024.02.005","title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":312,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"AstraZeneca; AstraZeneca United States","keywords":"Durvalumab; Tremelimumab; Medicine; Sorafenib; Hepatocellular carcinoma; Oncology; Internal medicine; Confidence interval; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009891754,0.0002881751,0.00108612,0.0002473724,0.00005532591,0.0000190938,0.0002679687,0.0002084231,0.00057952],"category_scores_gemma":[0.000103508,0.0002092531,0.0002819186,0.0004780432,0.0001318616,0.0001131764,0.0001394563,0.0003699271,0.00004244277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001271567,"about_ca_system_score_gemma":0.0006024456,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009642097,"about_ca_topic_score_gemma":0.001007453,"domain_scores_codex":[0.9971997,0.0005459019,0.0008263083,0.0005039022,0.0004648071,0.0004594106],"domain_scores_gemma":[0.9982516,0.000646563,0.0001776861,0.0005943755,0.0001954996,0.0001343369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005383504,0.004286146,0.9594223,0.0001374199,0.0009830174,0.003717398,0.005546974,0.000008575412,0.003465608,0.0003990552,0.003222299,0.01342768],"study_design_scores_gemma":[0.2213405,0.09702021,0.3886212,0.001312238,0.004966016,0.0002125182,0.01748811,0.0835152,0.0672627,0.003097023,0.1132424,0.001921887],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884501,0.00456132,0.00001335327,0.002506186,0.0003671436,0.001364446,0.00009348393,0.00004180469,0.002602237],"genre_scores_gemma":[0.9985746,0.0004185324,0.00006726886,0.0002060809,0.0001966377,0.00009380313,0.0001302422,0.00004596997,0.0002668875],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5708011,"threshold_uncertainty_score":0.9969528,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1856405556875463,"score_gpt":0.3639313170887483,"score_spread":0.178290761401202,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}